Immunohistochemistry PD-L1 22C3 Test
Short Name: PD-L1 22C3 Test
Also known as: PD-L1 22C3 Assay, PDL1 Expression Test, PD-L1 Companion Diagnostic
Immunohistochemistry PD-L1 22C3 Test test available at DNA Labs India for ₹16,380. Uses Immunohistochemistry (IHC) on Tumor tissue in 10% formal-saline or formalin-fixed paraffin-embedded (FFPE) block samples. Results in Reports are typically available within 5-7 working days after sample receipt.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The primary purpose of the Immunohistochemistry PD-L1 22C3 Test is to identify patients with PD-L1 expressing tumors who may benefit from immune checkpoint inhibitor therapies. It serves as a companion diagnostic to guide treatment decisions, optimize therapeutic outcomes, and avoid unnecessary side effects in cancer management.
- Test Code
- 906
- Price
- ₹16,380
- Sample Type
- Tumor tissue in 10% formal-saline or formalin-fixed paraffin-embedded (FFPE) block
- Result Time
- Reports are typically available within 5-7 working days after sample receipt.
- Fasting Required
- No
- Method
- Immunohistochemistry (IHC)
Sample Collection
Ensure the biopsy sample is collected appropriately and preserved in 10% formal-saline or as an FFPE block. Provide a copy of the histopathology report, biopsy site details, and clinical history.
Method: Biopsy Collection
Laboratory Analysis
Standard biopsy procedure performed by a healthcare professional; tissue sample is collected from the suspected tumor area.
Report Delivery
The biopsy sample is labeled and shipped at room temperature to the laboratory for analysis. Results are typically available within 5-7 working days.
Timeline: Reports are typically available within 5-7 working days after sample receipt.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of the Immunohistochemistry PD-L1 22C3 Test is to identify patients with PD-L1 expressing tumors who may benefit from immune checkpoint inhibitor therapies. It serves as a companion diagnostic to guide treatment decisions, optimize therapeutic outcomes, and avoid unnecessary side effects in cancer management.
How to Prepare
- Submit tumor tissue in 10% formal-saline or as a formalin-fixed paraffin-embedded (FFPE) block
- Ship the sample at room temperature
- Include a copy of the histopathology report, specify the biopsy site, and provide relevant clinical history
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"The PD-L1 22C3 test is crucial for identifying patients who may benefit from immunotherapy, such as Pembrolizumab, in various cancers including lung and gastric cancers."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Insufficient tumor tissue in the sample
- Improper fixation or preservation
- Missing clinical information or histopathology report
- Sample contaminated or degraded
Understanding Your Results
PD-L1 Negative: Lower likelihood of response to PD-1/PD-L1 inhibitors as monotherapy in some cancers.
PD-L1 Low Expression: May benefit from combination therapies; response varies by cancer type.
PD-L1 High Expression: Higher likelihood of response to immunotherapy; often eligible for first-line treatment in NSCLC.
Consult an oncologist if diagnosed with cancer to discuss whether PD-L1 testing is appropriate for treatment planning, especially when considering immunotherapy options.
Limitations
- ⚠Not a standalone diagnostic; requires correlation with clinical and histopathological findings
- ⚠PD-L1 expression may vary across different tumor regions
- ⚠Companion diagnostic use is limited to specified indications and treatments
- ⚠Test results may be affected by prior therapies
Risks & Considerations
- ●No direct risks from the laboratory test; risks associated with biopsy collection include infection, bleeding, or discomfort at the biopsy site.
Interfering Factors
- ●Poor tissue fixation or preservation
- ●Inadequate biopsy sample size
- ●Tumor heterogeneity
- ●Storage and shipping conditions
Frequently Asked Questions
What is the PD-L1 22C3 Test?
Why is this test important for cancer treatment?
Which cancers is the PD-L1 22C3 Test indicated for?
How is the test performed?
What is the cost of the PD-L1 22C3 Test at DNA Labs India?
Who should undergo this test?
How long does it take to get results?
Is home collection available for this test?
What sample is required for the test?
Can this test predict response to immunotherapy?
Are there any risks associated with the biopsy?
How should I prepare for the test?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.